SCHEMBL21331791

SCHEMBL21331791

CCC(Oc1ccc(C=O)cc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 1/20 0.51
IGLV6-57 P01721 1/20 0.50
LTB4R Q15722 1/20 0.45
LTB4R2 Q9NPC1 1/20 0.45
SLC7A5 Q01650 1/20 0.45
SLC6A4 P31645 8/20 0.44
DRD1 P21728 2/20 0.44
ALDH1A1 P00352 3/20 0.43
CYP2A6 P11509 2/20 0.43
ALKBH1 Q13686 1/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HRH3 Q9Y5N1 2/20 0.40
NPC1 O15118 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 2/20 0.40
MTOR P42345 2/20 0.40
RAB9A P51151 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8192464 0.83 IGLV6-57 (0.46) IGLV6-57SLC7A5SLC6A4DRD1ALKBH1
SCHEMBL28788669 0.83 PPARG (0.48) ALDH1A3DRD1
SCHEMBL2785535 0.82 SLC6A4 (0.59) IGLV6-57SLC7A5SLC6A4DRD1ALKBH1
SCHEMBL11156309 0.81 LTB4R (0.55) IGLV6-57LTB4RLTB4R2ALDH1A1LMNA
SCHEMBL10021745 0.80 IGLV6-57 (0.51) IGLV6-57SLC7A5SLC6A4DRD1LMNA
SCHEMBL7549785 0.80 SLC6A4 (0.53) IGLV6-57SLC7A5SLC6A4DRD1LMNA
SCHEMBL24512637 0.78 ALDH1A3 (0.61) ALDH1A3IGLV6-57LTB4RLTB4R2DRD1
SCHEMBL8460330 0.78 SLC7A5 (0.51) IGLV6-57SLC7A5SLC6A4SLC6A2SLC6A3
SCHEMBL3033350 0.78 ALDH1A3 (0.61) ALDH1A3IGLV6-57LTB4RLTB4R2DRD1
SCHEMBL30110780 0.78 ALDH1A3 (0.61) ALDH1A3IGLV6-57LTB4RLTB4R2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108409837-B Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof 上海来益生物药物研究开发中心有限责任公司 2021-09-24 CN claimed
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2021-04-01 US claimed
EP-3763728-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) 2021-01-13 EP claimed
WO-2019170046-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海来益生物药物研究开发中心有限责任公司 2019-09-12 WO claimed
US-11696937-B2 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2023-07-11 US disclosed
CN-108409837-B Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof 上海来益生物药物研究开发中心有限责任公司 2021-09-24 CN disclosed
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) 2021-04-01 US disclosed
EP-3763728-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) 2021-01-13 EP disclosed
WO-2019170046-A1 GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海来益生物药物研究开发中心有限责任公司 2019-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210093691-A1 Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof VIP, CUTA, MGAM ALDH1A3 4254/4885IGLV6-57 798/4885LTB4R 1508/4885
US-11696937-B2 Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof VIP, CUTA, MGAM ALDH1A3 4254/4885IGLV6-57 798/4885LTB4R 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.